Lexicon Pharmaceuticals, Inc.
LXRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $31,081 | $1,204 | $139 | $298 |
| % Growth | 2,481.5% | 766.2% | -53.4% | – |
| Cost of Goods Sold | $616 | $58,972 | $52,516 | $55,046 |
| Gross Profit | $30,465 | -$57,768 | -$52,377 | -$54,748 |
| % Margin | 98% | -4,798% | -37,681.3% | -18,371.8% |
| R&D Expenses | $84,480 | $58,887 | $52,816 | $55,046 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $131,902 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $11,200 | $55,095 | -$4,433 | -$22,704 |
| Operating Expenses | $227,582 | $113,982 | $48,383 | $32,342 |
| Operating Income | -$197,117 | -$171,750 | -$100,760 | -$87,090 |
| % Margin | -634.2% | -14,265% | -72,489.2% | -29,224.8% |
| Other Income/Exp. Net | -$3,286 | -$5,369 | -$1,184 | -$668 |
| Pre-Tax Income | -$200,403 | -$177,119 | -$101,944 | -$87,758 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$200,403 | -$177,119 | -$101,944 | -$87,758 |
| % Margin | -644.8% | -14,710.9% | -73,341% | -29,449% |
| EPS | -0.63 | -0.8 | -0.62 | -0.61 |
| % Growth | 21.3% | -29% | -1.6% | – |
| EPS Diluted | -0.63 | -0.8 | -0.62 | -0.61 |
| Weighted Avg Shares Out | 320,031 | 221,130 | 165,733 | 145,652 |
| Weighted Avg Shares Out Dil | 320,031 | 221,130 | 165,733 | 145,652 |
| Supplemental Information | – | – | – | – |
| Interest Income | $12,293 | $7,732 | $1,596 | $134 |
| Interest Expense | $15,579 | $13,101 | $2,780 | $802 |
| Depreciation & Amortization | $534 | $554 | $427 | $292 |
| EBITDA | -$184,290 | -$169,756 | -$100,033 | -$86,798 |
| % Margin | -592.9% | -14,099.3% | -71,966.2% | -29,126.8% |